journalsPermissions.nav Therapeutic Advances in Medical Oncology Review

Prostate cancer remains the most common non-cutaneous malignancy and the second leading cause of cancer death in American men [Jemal et al. 2010]. While many men present with local-ized and potentially curable disease, the large numbers of deaths from prostate cancer are driven by the development of metastatic disease. Unfortunately, there are no curative options for metastatic prostate cancer and treatment of met-astatic disease remains a significant public health burden. The initial treatment of choice for meta-static prostate cancer is androgen deprivation. While prostate cancer typically responds to the initiation of hormonal therapy, resistance is inev-itable, leading to a state termed castrate-resistan